Filing Flows › Health Care › Jupiter Neurosciences (JUNS)
Jupiter Neurosciences (JUNS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Jupiter Neurosciences (JUNS) Q2 2026 earnings results →
Jupiter Neurosciences made $24K in Q2 2026. Operating margin n/m, net loss $2.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $24K in Q2 2026, up 30% from the previous quarter.
Gross margin was 86.9%. Operating costs exceeded revenue by $2.7M, an operating margin of -11313.4%. The quarter ended with a net loss of $2.3M, wider than the previous quarter's $2.1M loss. Non-operating items added $469K, -21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.3M. Non-cash charges added back $491K of share-based compensation. Working capital and other items used $512K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $24K | — | n/m | −$2.3M | −$2.3M |
| Q1 2026 | 10-Q | May 14, 2026 | $19K | — | n/m | −$2.1M | −$1.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Jupiter Neurosciences
This Business section, along with other sections of this Annual Report on Form 10-K, includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data and we do not make any representation as to the accuracy of the information. Unless the context otherwise requires, “JNS,” “we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences, Inc., a Delaware corporation.
In its own words, from its 10-K, filed Apr 1, 2026.
Jupiter Neurosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| JUNS Jupiter Neurosciences | Q2 2026 | $24K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Jupiter Neurosciences 10-Q on SEC EDGAR · CIK 1679628 · Pharmaceutical Preparations
More on JUNS
History
Every quarter: Q2 2026 results · Q1 2026 results